Can-Fite Biopharma Ltd (AMEX:CANF) headquartered in Petah-Tikva, will host a conference call for the investment community to discuss the 2Q20 earnings result on 27th August 2020 at 4:15 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit public.viavid.com/player/index.php?id=141284
Individuals interested in participating in the audio call may dial the listen only number(s) 1-877-423-9813 Toll Free, (United States), with passcode : 13708494
Earnings Expectation
Can-Fite Biopharma Ltd is reporting second quarter financial results on Thursday 27th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, CANF is expected to report 2Q20 loss of $ 0.33 per share from revenue of $ 0.25 million.
For the full year, analysts anticipate top line of $ 0.95 million, while looking forward to loss of $ 1.75 per share bottom line.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The companys lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.
